IRISanRaf

PICCONI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.357
AS - Asia 2.113
EU - Europa 558
SA - Sud America 132
Continente sconosciuto - Info sul continente non disponibili 67
AF - Africa 33
OC - Oceania 14
Totale 6.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.948
TR - Turchia 944
CN - Cina 528
SG - Singapore 497
CA - Canada 395
IT - Italia 143
BR - Brasile 119
CZ - Repubblica Ceca 119
DE - Germania 76
EU - Europa 67
GB - Regno Unito 65
IE - Irlanda 44
IN - India 37
HK - Hong Kong 23
FI - Finlandia 18
BD - Bangladesh 15
JP - Giappone 14
ZA - Sudafrica 14
RU - Federazione Russa 13
NL - Olanda 12
ES - Italia 11
FR - Francia 11
MX - Messico 11
RO - Romania 10
UA - Ucraina 10
VN - Vietnam 9
AU - Australia 8
DK - Danimarca 6
NZ - Nuova Zelanda 6
SC - Seychelles 6
TW - Taiwan 6
SE - Svezia 5
CO - Colombia 4
JO - Giordania 4
MA - Marocco 4
PK - Pakistan 4
BE - Belgio 3
EG - Egitto 3
IL - Israele 3
PL - Polonia 3
PS - Palestinian Territory 3
SA - Arabia Saudita 3
AZ - Azerbaigian 2
BB - Barbados 2
CL - Cile 2
GR - Grecia 2
ID - Indonesia 2
IQ - Iraq 2
IR - Iran 2
KE - Kenya 2
LK - Sri Lanka 2
NG - Nigeria 2
PH - Filippine 2
UY - Uruguay 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
DZ - Algeria 1
EC - Ecuador 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
SN - Senegal 1
TJ - Tagikistan 1
Totale 6.274
Salva come PNG Salva come JPEG
Città #
Kocaeli 807
San Mateo 688
Toronto 373
Wilmington 202
Houston 181
Dallas 162
Singapore 161
Chandler 159
Santa Clara 158
Lawrence 139
Princeton 139
Ashburn 122
Olomouc 119
Beijing 109
Fairfield 84
Shanghai 59
Seattle 49
Woodbridge 48
Guangzhou 37
Los Angeles 35
Munich 35
Redwood City 34
The Dalles 25
Hong Kong 23
Shenzhen 23
Cambridge 22
Dublin 22
Columbus 21
Rome 20
Brooklyn 19
Chicago 19
Falls Church 19
New York 18
São Paulo 18
Jiaxing 15
Helsinki 13
London 11
Tokyo 11
Wuhan 11
Chennai 10
Constanta 10
Pune 10
Council Bluffs 9
Johannesburg 9
Rui'an 7
Belo Horizonte 6
Boston 6
Charlotte 6
Dongyang 6
Montreal 6
Wuxi 6
Bristol 5
Haining 5
Padova 5
Phoenix 5
Saint Louis 5
Stockholm 5
Washington 5
Amman 4
Atlanta 4
Dhaka 4
Espoo 4
Florence 4
Genoa 4
Mexico City 4
Nanjing 4
Quanzhou 4
Redmond 4
San Francisco 4
Shaoxing 4
Taipei 4
Trento 4
Xi'an 4
Amsterdam 3
Ankara 3
Boardman 3
Buffalo 3
Franz Josef 3
Hangzhou 3
Hanoi 3
Istanbul 3
Kunming 3
Kyiv 3
Madrid 3
Nantong 3
New Delhi 3
Opelousas 3
Poplar 3
Taizhou 3
Warsaw 3
Zhengzhou 3
Abuja 2
Assago 2
Baku 2
Bismarck 2
Bogotá 2
Bolzano 2
Brasília 2
Bridgetown 2
Campinas 2
Totale 4.468
Salva come PNG Salva come JPEG
Nome #
Direct and indirect pathways of basal ganglia: a critical reappraisal 180
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 141
Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease 88
A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation 87
Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons 83
Corrigendum: Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons 76
Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. 73
New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease 69
Quantal release of dopamine and action potential firing detected in midbrain neurons by multifunctional diamond-based microarrays 69
Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. 63
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. 61
Dopamine drives binge-like consumption of a palatable food in experimental parkinsonism. 59
Motor Complications in Parkinson's Disease: Striatal Molecular and Electrophysiological Mechanisms of Dyskinesias 59
Synaptic dysfunction in Parkinson's disease 57
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 57
BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior 56
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuo-spatial memory alteration. 56
Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors 55
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. 54
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap 53
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 53
Dopaminergic control of synaptic plasticity in the dorsal striatum 52
NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. 52
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. 52
Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission 52
Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum 52
Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease 52
NMDA receptor G1uN2D subunit participates to levodopa-induced dyskinesia pathophysiology 52
Theta-burst stimulation and striatal plasticity in experimental parkinsonism 51
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. 51
Early Synaptic Dysfunction in Parkinson's Disease: Insights From Animal Models 51
Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine 50
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts 50
Interaction between basal ganglia and limbic circuits in learning and memory processes 50
Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates 50
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities 50
An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease 50
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias 50
A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity 50
Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. 49
A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication 49
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 49
N-Methyl-D-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons 49
The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D-2/A(2A) Receptor Interaction in the Striatum: Implications for Parkinson's Disease 49
A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. 49
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias 48
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit 48
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism 47
Striatal spreading depolarization: possible implication in L-DOPA-induced dyskinetic like-behavior. 47
New Synaptic and Molecular Targets for Neuroprotection in Parkinson's Disease 47
Tissue plasminogen activator is required for corticostriatal long-term potentiation 46
Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia? 46
Mechanisms underlying dopaminergic control of cortico-striatal synaptic transmission 46
Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment 46
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. 46
Striatum-hippocampus balance: From physiological behavior to interneuronal pathology 46
Neural networks and synaptic plasticity in Parkinson's disease: beyond motor deficits 46
Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons 46
Prenatal stress and hippocampal BDNF expression: a fading imperative 46
Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. 46
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia 45
Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice 45
Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression 45
Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors 45
Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. 45
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine 45
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? 44
Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons 44
Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum 44
Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice 43
NR2B subunit exerts a critical role in postischemic synaptic plasticity. 43
Dopamine-mediated regulation of corticostriatal synaptic plasticity. 43
Unilateral dopamine denervation blocks corticostriatal LTP 42
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia 42
Stimulation of D1/PKA/DARPP-32/PP-1 pathway is required for corticostriatal LTD and LTP 42
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission 42
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission 41
Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. 41
Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia 41
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia 41
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia 41
Molecular mechanisms underlying levodopa-induced dyskinesia. 41
mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP 41
Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease 41
Plastic abnormalities in experimental Huntington's disease 41
Targeting Metabotropic Glutamate Receptors as a New Strategy Against Levodopa-Induced Dyskinesia in Parkinson's Disease? 41
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. 41
Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. 40
Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons 40
NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients 40
Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. 40
Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study 40
Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid 40
Hyperkinetic disorders and loss of synaptic downscaling 40
Deficits of glutamate transmission in the striatum of experimental hemiballism. 40
FUNCTIONAL INTERACTIONS WITHIN STRIATAL MICROCIRCUIT IN ANIMAL MODELS OF HUNTINGTON'S DISEASE 39
Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity 39
L-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via beta-adrenergic receptors 39
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment 39
Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. 38
Totale 5.121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.199
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.199
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.215 0 0 33 11 44 92 70 22 35 48 807 53
2021/20221.349 11 369 372 1 9 12 89 139 36 279 11 21
2022/2023647 308 15 13 54 33 16 5 21 29 63 82 8
2023/2024571 0 2 17 127 26 17 15 37 3 21 70 236
2024/20251.466 54 338 98 68 92 234 41 98 191 20 58 174
2025/2026505 258 244 3 0 0 0 0 0 0 0 0 0
Totale 6.524